| Ihre Aktion | suchen [und] | ([PPN] Pica-Produktionsnummer) | | 1 Treffer |
PPN: |
||
Titel: |
Targeted Therapeutics in Melanoma / edited by Thomas F. Gajewski, F. Stephen Hodi
|
|
Verfasser: |
||
Sonst. Personen: |
||
Ort/Jahr: |
New York, NY : Springer Science+Business Media, LLC, 2012 |
|
Sprache/n: |
Englisch |
|
Umfang: |
Online-Ressource : v.: digital |
|
Schriftenreihe: |
||
Anmerkung: |
Description based upon print version of record |
|
Mehr zum Titel: |
Targeted Therapeuticsin Melanoma; Preface; Cracking the Melanoma Nut; Acknowledgments; Contents; Contributors; Part I: Advances in Melanoma Biology; Chapter 1: Molecular Targets and Subtypes in Melanoma; Introduction; BRAF; NRAS; PI3K-AKT Pathway; c-KIT; GNAQ; Conclusions; References; Chapter 2: Melanoma Genomics; Gene Expression Profiling of Distinct Phases of Melanoma Progression; Gene Expression Profiles of Primary Melanoma; Gene Expression Profiling of Metastatic Melanoma; Conclusions; References; Chapter 3: Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma
Evidence for Existence of Biologic Subsets of MelanomaKinase Mutations and Clinical Response to Kinase Inhibitors; B-Raf; c-kit; New Pathways Showing Heterogeneity Among Individual Melanoma Patients; Gene Expression Profiling and Clinical Response to Melanoma Vaccines; Molecular Features Associated with Response to Chemotherapy; Biomarkers as a Tool to Determine Mechanisms of Therapeutic Resistance; Predictive Biomarkers from Non-Tumor Tissue: Serum and Germline DNA; The Evolving Future of Melanoma Therapy; References; Part II: Signaling Molecules as Molecular Targets
Chapter 4: KIT as a Therapeutic Target for MelanomaIntroduction; KIT as a Proto-Oncogene; The Role of KIT in Cancer; KIT Tyrosine Kinase Inhibitors; Overcoming Resistance to Tyrosine Kinase Inhibition; Is KIT Amplification or Mutation More Important?; Conclusions; References; Chapter 5: Targeted Inhibition of B-Raf; Introduction; The MAPK Pathway; BRAF Mutations in Melanoma; Preclinical Studies; RAF Inhibition of BRAF Wild-Type Cells Leads to Activation of the MAPK Pathway; RAF Inhibition of BRAF-Mutated Melanoma Causes Melanoma Cell Death
Clinical Studies with the RAF Inhibitor PLX4032 (RO5185426)Spectrum of BRAF Inhibitors in Clinical Trials; MEK Inhibition as a Strategy for Targeting BRAF Mutant Melanoma; Resistance Mechanisms Observed in Clinical Trials; Future Directions for BRAF Inhibitors; References; Chapter 6: The Notch and b -Catenin Pathways; Notch Signaling; Notch and Cancer; Targeting Notch in Melanoma; b -catenin Signaling; Wnt/ b -catenin and Cancer; Targeting b -catenin in Melanoma; Perspective; References; Chapter 7: STAT3 and Src Signaling in Melanoma; Introduction; STAT3 and Src Signaling in Melanoma
STAT3/Src Regulation of Tumor Cell GrowthSTAT3 and Src Activity Promote Angiogenesis and Metastasis in Melanoma; STAT3 Signaling in Tumor-Associated Immune Cells: Their Role in Melanoma Development; Treatment of Melanoma by STAT3-Targeted Therapy; Inhibition of STAT3 Activation in Melanoma via Small-Molecule Inhibitors; Conclusions; References; Chapter 8: Targeting the mTOR, PI3K, and AKT Pathways in Melanoma; mTor Overview: Normal Functions and Genetic Alterations of Importance in Melanoma; Upstream Effectors of mTOR Activation: PTEN, PI3K, and AKT
mTOR Complexes and Downstream Events: Control of Transcription
|
|
ISBN: |
978-1-61779-407-0
Weitere Ausgaben: 978-1-61779-406-3 (Printausgabe)
|
|
Identifier: |
||
Schlagwörter: |
||
Klassifikation: |
Library of Congress Classification: RC280.M37 T37 2012
Dewey Decimal Classification: 616.99477
National Library of Medicine Classification: QZ 267
|
|
 |
Inhalt:
|
|
Links zum Titel:
|
http://dx.doi.org/10.1007/978-1-61779-407-0 [Volltext] (Lizenzpflichtig)
|
|
Sekundärausgabe: |
Online-Ausg. |
|
Gesamttitel: |
||
Produktsigel: |
ZDB-2-SME 2012 |
 |
